SGLT2 inhibitors (SGLT2i), also called gliflozins, inhibit the activity of the Sodium Glucose Cotransporter 2 (SGLT2) in renal tubules, ultimately leading to glucosuria. The gene discussed is SLC5A2; the disease is Glycosuria.